Tirzepatide 10mg
EXPRESS Apple Pay afterpay
Tirzepatide at a glance
Understanding dual incretin signalling
Tirzepatide is distinguished by its activity at both the GIP and GLP-1 receptors. These receptors participate in metabolic signalling and the regulation of glucose-dependent insulin responses.
GIP receptor activity
The GIP receptor participates in glucose-dependent insulin signalling. Researchers investigate its contribution to metabolic regulation and interactions with GLP-1 pathways.
GLP-1 receptor activity
GLP-1 receptor signalling is associated with glucose-dependent insulin secretion, glucagon regulation, appetite-related pathways and gastric motility.
Metabolic research
Clinical research using approved formulations has examined blood-glucose markers, body weight, cardiometabolic measurements and metabolic signalling.
Published clinical outcomes apply to studied pharmaceutical formulations and populations. They do not demonstrate equivalent effects from Halo Bio research material.
What have tirzepatide studies investigated?
Tirzepatide has been evaluated in large randomised clinical trials examining type 2 diabetes and obesity. The trials used pharmaceutical formulations manufactured and administered under controlled clinical protocols.
Jastreboff et al. ยท SURMOUNT-1 (2022)
A 72-week randomised study involving 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, investigated changes in body weight. Mean reductions in the treatment-regimen analysis were 15.0%, 19.5% and 20.9% in the three tirzepatide treatment groups, compared with 3.1% for placebo.
Frรญas et al. ยท SURPASS-2 (2021)
A 40-week randomised trial compared pharmaceutical tirzepatide with semaglutide in adults with type 2 diabetes receiving metformin. Researchers evaluated glycated haemoglobin (HbA1c), body weight and other clinical outcomes.
Pharmacological and receptor research
Mechanistic investigations have characterised tirzepatide’s dual receptor activity, peptide structure and pharmacological properties. Its fatty diacid side-chain contributes to albumin binding and prolonged exposure in studied formulations.
The clinical findings above are not purity, safety or performance claims for Halo Bio’s separately supplied 10mg research vial.
Tirzepatide vs Semaglutide
Both compounds have been investigated in incretin-related metabolic research, but they differ in molecular structure and receptor pharmacology.
| Characteristic | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor activity | GIP and GLP-1 | GLP-1 |
| Peptide chain | 39 amino acids | 31 amino acids |
| Structural feature | Modified GIP-based peptide with lipid side-chain | Modified GLP-1 analogue with lipid side-chain |
| Research context | Dual incretin signalling | GLP-1 signalling |
These are distinct compounds. Research findings for one should not be transferred to the other without supporting evidence.
Melbourne stock. Nationwide dispatch.
Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is provided during fulfilment, with delivery times dependent on destination and carrier.
Tirzepatide research FAQs
Tirzepatide is a synthetic 39-amino-acid peptide with dual GIP and GLP-1 receptor agonist activity.
It refers to activity at both GIP and GLP-1 receptors, which participate in glucose-dependent insulin signalling and metabolic regulation.
Published studies have examined glucose regulation, HbA1c, weight-related outcomes and incretin receptor signalling.
No. Tirzepatide activates GIP and GLP-1 receptors, whereas semaglutide is a GLP-1 receptor agonist. Their molecular structures differ.
It refers to the nominal labelled quantity of research material in the vial. It does not by itself verify measured content or purity.
No. Those are regulated prescription medicine formulations containing tirzepatide. Halo Bio’s lyophilised research vial is a separate material and is not interchangeable with those products.
No direct equivalence can be assumed. Clinical outcomes concern specific pharmaceutical formulations, defined study populations and controlled protocols.
Batch-specific analytical results should be established using documentation identifying the actual tested material. A nominal label quantity or unrelated supplier’s report does not establish batch purity.
No. Halo Bio supplies this material for laboratory research only, not for consumption, injection, self-administration or clinical treatment.
Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day after payment confirmation.
Independent scientific publications
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
Read publication โ - Frรญas JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021.
Read publication โ - US Food and Drug Administration. Zepbound (tirzepatide) prescribing information.
View documentation โ - PubChem. Tirzepatide, Compound CID 156588324.
View molecular data โ
Laboratory research use only.
Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. Published clinical findings concern regulated pharmaceutical formulations and do not establish identity, purity, sterility, safety or performance of this separately supplied research material.